期刊文献+

贝前列素联合西地那非对COPD合并肺动脉高压的临床研究

Study on the therapeutic effects of beraprost combined with sildenafil on COPD complicated by pulmonary hypertension
下载PDF
导出
摘要 目的探究患有慢性阻塞性肺疾病(COPD)合并肺动脉高压的患者使用贝前列素与西地那非联合治疗方案的临床效果。方法选取2014年6月至2015年12月收集住院的COPD合并肺动脉高压的患者80例,采用随机分组法分为对照组、贝前列素组、西地那非组、贝前列素与西地那非联合用药组,每组20例;对比分析4组患者接受治疗后1、3、6个月的治疗效果。结果贝前列素组、西地那非组与联合治疗组患者经过治疗运动耐力显著提高,患者的血气分析、血液流变性指标、心肌酶指标、血浆脑钠素(BNP)、左心室射血分数(LVEF)、右心房压、左右心室大小、PAP、6 min步行距离、肺功能检查均有明显改善。结论通过使用两种联合药物作用的疗效的评估,可以一定程度降低COPD合并肺动脉高压患者的发病次数,降低其病死率,提高生活质量,具有较好的社会经济效应。 Objective To investigate the therapeutic effects of beraprost combined with sildenafil on chronic obstructive lung disease (COPD) complicated by pulmonary hypertension. Methods Eighty patients with COPD complicated by pulmonary hypertension who were treated in our hospital from June 2014 to December 2015 were randomly divided into control group, beraprost group, sildenafil group, combination medication group ( beraprost + sildenafil), with 20 patients in each group. The therapeutic effects on 1,3,6 months after treatment were observed and compared among the four groups. Results After treatment, the exercise tolerance of patients in beraprost group, sildenafil group, combination medication group was significantly improved, moreover, the blood gas analysis parameters, hemorheology indexes, myocardial enzyme indexes, plasma brain natriuretic peptide (BNP), left ventriculm" ejection fraction (LVEF), fight atrial pressure, left ventricular size, PAP, 6-min walking distance and lung function were significantly improved in the three groups ( P 〈 0.05 ). Conclusion The heraprost combined with sildenafil can decrease disease attack frequency ,reduce death rate and improve life quality of patients with COPD complicated by pulmonary hypertension,thus,which has better social and economic effects.
作者 马碧蔓 温琼娜 苏伟强 庞土富 陈虹 林辉斌 许志成 MA Biman WEN Qiongna SU Weiqiang et al(Department of Respiratory Medicine, People 's Central Hospital of Zhanjiang City, Guangdong , Zhanjiang 524037, Chin)
出处 《河北医药》 CAS 2017年第22期3392-3395,共4页 Hebei Medical Journal
基金 湛江市非资助科技攻关计划项目(编号:2014B01141)
关键词 贝前列素 西地那非 COPD 肺动脉高压 脑钠素 beraprost sildenafil COPD pulmonary hypertension brain natriuretic peptide
  • 相关文献

参考文献5

二级参考文献55

  • 1陈昆峰.遗传性出血性毛细血管扩张症死亡1例[J].中国医师杂志,2005,7(2):288-288. 被引量:2
  • 2徐希奇,赵红,荆志成.遗传性出血性毛细血管扩张症合并肺动脉高压的临床表型与分子遗传学特点[J].医学研究通讯,2005,34(3):63-66. 被引量:1
  • 3Simonneau G,Galiè N,Rubin LJ,et al.Clinical classification of pulmonary hypertension.J Am Coll Cardiol,2004,43:S5-S12.
  • 4Humbert M,Sitbon O,Simonneau G.Treatment of pulmonary arterial hypertension.N Engl J Med,2004,351:1425-1436.
  • 5Kuhn KP,Byme DW,Arbogast PG,et al.Outcome in 91consecutive patients patients with pulmonary arterial hypertension receiving epoprostenol.Am J Respir Crit Care Med,2003,167:580-586.
  • 6Rubin LJ,Badesch DB,Barst RJ,et al.Bosentan therapy for pulmonary arterial hypertension.N Engl J Med,2002,346:896-903.
  • 7Kataoka M,Satoh T,Manabe T,et al.Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.Circ J,2005,69:461-465.
  • 8Sastry BK,Narasimhan C,Reddy NK,et al.Clinical efficacy of sildenafil in primary pulmonary hypertension:a randomized,placebo-controlled,double-blind,crossover study.J Am Coll Cardiol,2004,43:1149-1153.
  • 9Galiè N,Ghofrani HA,Torbicki A,et al.Sildenafil citrate therapy for pulmonary arterial hypertension.N Engl J Med,2005,353:2148-2157.
  • 10Garg N,Sharma MK,Sinha N.Role of oral sildenafil in severe pulmonary arterial hypertension:clinical efficacy and dose response relationship.Int J Cardiol,2007,120:306-313.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部